Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

orpha-devel handels und vertriebs gmbh, wintergasse 85/1b, purkersdorf, austrija - treprostinil - otopina za infuziju - 10 mg/ml - urbroj: jedan ml otopine sadrži 10 mg treprostinila u obliku treprostinilnatrija

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

orpha-devel handels und vertriebs gmbh, wintergasse 85/1b, purkersdorf, austrija - treprostinil - otopina za infuziju - 2,5 mg/ml - urbroj: jedan ml otopine sadrži 2,5 mg treprostinila u obliku treprostinilnatrija

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

orpha-devel handels und vertriebs gmbh, wintergasse 85/1b, purkersdorf, austrija - treprostinil - otopina za infuziju - 5 mg/ml - urbroj: jedan ml otopine sadrži 5 mg treprostinila u obliku treprostinilnatrija

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

medical developments ned b.v., strawinskylaan 411, wtc tower a, amsterdam, nizozemska - metoksifluran - para inhalata, tekućina - 99,9%,3 ml - urbroj: jedna bočica sadrži 3 ml metoksiflurana (99,9%)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

outsourcing-development s.p.r.l. rue du bercet 10 5660 couvin belgija -

Europska Unija - hrvatski - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Europska Unija - hrvatski - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.

Europska Unija - hrvatski - EMA (European Medicines Agency)

ammtek - glibenklamid - Šećerna bolest - lijekovi koji se koriste u dijabetesu - amglidia indiciran za liječenje šećerne bolesti kod novorođenčadi, za primjenu kod novorođenčadi, dojenčadi i djece. sulfonilureje amglidia, kao što je prikazano biti učinkovit u bolesnika s mutacije u genima, kodiranje β-stanica atp-osjetljive kalija kanala dijabetesom i kromosoma 6q24 povezane s транзиторной neonatalna .

Europska Unija - hrvatski - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doksorubicin hidroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastična sredstva - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).